¥2,373.50
0.36%
Tokyo, Sep 18, 11:30 am JST. Closed.
ISIN
JP3942400007
Symbol
4503
Index

Astellas Pharma Target price 2026 - Analyst rating & recommendation

Astellas Pharma Classifications & Recommendation

Buy
37%
Hold
58%
Sell
5%

Astellas Pharma Price Target

Target Price ¥2,504.10
Price ¥2,383.50
Potential
Number of Estimates 17
17 Analysts have issued a price target Astellas Pharma 2027 . The average Astellas Pharma target price is ¥2,504.10. This is higher than the current stock price. The highest price target is
¥3,255.00 36.56%
register free of charge
, the lowest is
¥1,717.00 27.96%
register free of charge
.
A rating was issued by 19 analysts: 7 Analysts recommend Astellas Pharma to buy, 11 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2027 of . Most analysts recommend the Astellas Pharma stock at Hold.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Billion ¥ 2,139.25 2,361.44
11.87% 10.39%
EBITDA Margin 26.89% 29.37%
28.46% 9.22%
Net Margin 13.63% 15.05%
413.55% 10.43%

16 Analysts have issued a sales forecast Astellas Pharma 2027 . The average Astellas Pharma sales estimate is

¥2.4t
unlock
. This is
3.83% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥2.6t 13.89%
unlock
, the lowest is
¥2.2t 3.86%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 ¥2.1t 11.87%
2027
¥2.4t 10.39%
unlock
2028
¥2.2t 7.41%
unlock
2029
¥1.9t 11.15%
unlock

15 Analysts have issued an Astellas Pharma EBITDA forecast 2027. The average Astellas Pharma EBITDA estimate is

¥694b
unlock
. This is
13.25% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
¥939b 53.33%
unlock
, the lowest is
¥597b 2.52%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 ¥575b 43.71%
2027
¥694b 20.57%
unlock
2028
¥648b 6.52%
unlock
2029
¥536b 17.37%
unlock

EBITDA Margin

2026 26.89% 28.46%
2027
29.37% 9.22%
unlock
2028
29.65% 0.95%
unlock
2029
27.58% 6.98%
unlock

18 Astellas Pharma Analysts have issued a net profit forecast 2027. The average Astellas Pharma net profit estimate is

¥355b
unlock
. This is
2.63% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥473b 29.64%
unlock
, the lowest is
¥304b 16.70%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 ¥292b 474.49%
2027
¥355b 21.89%
unlock
2028
¥331b 6.93%
unlock
2029
¥244b 26.08%
unlock

Net Margin

2026 13.63% 413.55%
2027
15.05% 10.43%
unlock
2028
15.13% 0.53%
unlock
2029
12.59% 16.79%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share ¥ 162.77 198.19
476.38% 21.76%
P/E 12.03
EV/Sales 1.94

18 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma EPS is

¥198.19
unlock
. This is
2.68% lower
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
¥263.87 29.57%
unlock
, the lowest is
¥169.54 16.75%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 ¥162.77 476.38%
2027
¥198.19 21.76%
unlock
2028
¥184.45 6.93%
unlock
2029
¥136.36 26.07%
unlock

P/E ratio

Current 11.70 68.55%
2027
12.03 2.79%
unlock
2028
12.92 7.40%
unlock
2029
17.48 35.29%
unlock

Based on analysts' sales estimates for 2027, the Astellas Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.02 6.88%
2027
1.94 3.72%
unlock
2028
2.10 8.01%
unlock
2029
2.36 12.55%
unlock

P/S ratio

Current 1.87 19.82%
2027
1.80 3.68%
unlock
2028
1.95 8.00%
unlock
2029
2.19 12.56%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today